Yonkenafil |
Catalog No.GC70699 |
YonkenafilTunodafil은 뇌경색, 신경 기능 결손, 부종 및 경색 영역의 뉴런 손상을 효과적으로 감소시키는 새로운 인산 디에스테롤 5 (PDE5) 억제제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 804518-63-6
Sample solution is provided at 25 µL, 10mM.
Yonkenafil (4-32 mg/kg, i.v. daily for 7 days) improves behavioral outcomes after stroke and reduces cerebral infarct volume, inhibits neuronal apoptosis, and significantly enhances synaptic function in ischemic brain by modulating the expression of BDNF/TrkB and NGF/TrkA[1].
References:
[1]. Xuemei Chen, et al. Yonkenafil: a novel phosphodiesterase type 5 inhibitor induces neuronal network potentiation by a cGMP-dependent Nogo-R axis in acute experimental stroke. Exp Neurol. 2014 Nov;261:267-77.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *